Interleukin-6 Antagonists in COVID-19 Meta Analysis

Studien extrahiert aus dem Podcast von Rob Mac Sweeney

• 2021WHO REACTInfection & AntimicrobialsIn 10,930 patients hospitalized for COVID-19, IL-6 antagonists lowered 28-day all-cause mortality compared with usual care or placebo.
• 2021RECOVERYInfection & AntimicrobialsIn 4116 hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab reduced 28-day mortality compared with usual care alone.
• 2021REMAP-CAPICU & Critical CareIn 803 critically ill adults with Covid-19 on organ support, tocilizumab or sarilumab improved organ support-free days and survival compared with standard care.
• 2020BACC BayInfection & AntimicrobialsIn 243 hospitalized patients with moderate Covid-19 and hyperinflammation, tocilizumab did not reduce intubation or death compared with placebo.
• 2021TOCIBRASInfection & AntimicrobialsIn 129 adults hospitalised with severe or critical COVID-19, tocilizumab did not improve clinical status at 15 days compared with standard care alone.
• 2020REACTICU & Critical CareIn1703 critically ill patients with COVID-19,systemic corticosteroidsreduced28-day all-cause mortalitycompared withusual care or placebo.